Personalis, Inc. (NASDAQ:PSNL) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 7.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 675,974 shares of the company's stock after selling 57,339 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.77% of Personalis worth $2,373,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Lightspeed Management Company L.L.C. bought a new position in Personalis during the fourth quarter valued at approximately $47,169,000. Dimensional Fund Advisors LP lifted its position in Personalis by 144.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company's stock valued at $2,372,000 after buying an additional 242,141 shares during the period. Jane Street Group LLC lifted its position in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company's stock valued at $2,320,000 after buying an additional 237,033 shares during the period. 683 Capital Management LLC purchased a new position in Personalis during the fourth quarter valued at $775,000. Finally, Blue Water Life Science Advisors LP raised its position in shares of Personalis by 13.3% in the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company's stock worth $6,548,000 after purchasing an additional 132,900 shares during the last quarter. Institutional investors own 61.91% of the company's stock.

Personalis Stock Up 2.7%

Shares of Personalis stock traded up $0.18 on Tuesday, reaching $6.86. 1,446,409 shares of the stock were exchanged, compared to its average volume of 1,144,823. Personalis, Inc. has a twelve month low of $1.41 and a twelve month high of $7.79. The firm has a market capitalization of $605.88 million, a price-to-earnings ratio of -5.32 and a beta of 1.95. The business has a 50 day moving average price of $5.48 and a two-hundred day moving average price of $4.86.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 48.78% and a negative net margin of 98.10%. The business had revenue of $20.61 million during the quarter, compared to analysts' expectations of $17.41 million. Research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current year.

Analyst Ratings Changes

PSNL has been the subject of several recent analyst reports. HC Wainwright lifted their price target on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Craig Hallum initiated coverage on Personalis in a research note on Monday, March 17th. They set a "buy" rating and a $8.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $7.00 price objective on shares of Personalis in a research note on Thursday, April 10th. Finally, Guggenheim began coverage on Personalis in a report on Thursday, May 15th. They issued a "buy" rating and a $6.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $7.67.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.